

# Eugenio Cersosimo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3627677/publications.pdf>

Version: 2024-02-01

28  
papers

2,197  
citations

567144

15  
h-index

501076

28  
g-index

29  
all docs

29  
docs citations

29  
times ranked

3707  
citing authors

#	ARTICLE	IF	CITATIONS
1	Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes (<sc>EDICT</sc>). <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 899-907.	2.2	15
2	Dapagliflozin Impairs the Suppression of Endogenous Glucose Production in Type 2 Diabetes Following Oral Glucose. <i>Diabetes Care</i> , 2022, 45, 1372-1380.	4.3	4
3	Durability of Triple Combination Therapy Versus Stepwise Addition Therapy in Patients With New-Onset T2DM: 3-Year Follow-up of EDICT. <i>Diabetes Care</i> , 2021, 44, 433-439.	4.3	29
4	Antihyperglycemic Algorithms for Type 2 Diabetes: Focus on Nonglycemic Outcomes. <i>Diabetes Spectrum</i> , 2021, 34, 248-256.	0.4	1
5	Clinical Parameters, Fuel Oxidation, and Glucose Kinetics in Patients With Type 2 Diabetes Treated With Dapagliflozin Plus Saxagliptin. <i>Diabetes Care</i> , 2020, 43, 2519-2527.	4.3	3
6	Improved Beta Cell Glucose Sensitivity Plays Predominant Role in the Decrease in HbA1c with Cana and Lira in T2DM. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 3226-3233.	1.8	10
7	Anti-inflammatory and anti-proliferative action of adiponectin mediated by insulin signaling cascade in human vascular smooth muscle cells. <i>Molecular Biology Reports</i> , 2020, 47, 6561-6572.	1.0	6
8	Evidence Against an Important Role of Plasma Insulin and Glucagon Concentrations in the Increase in EGP Caused by SGLT2 Inhibitors. <i>Diabetes</i> , 2020, 69, 681-688.	0.3	23
9	Combination Therapy With Canagliflozin Plus Liraglutide Exerts Additive Effect on Weight Loss, but Not on HbA1c, in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2020, 43, 1234-1241.	4.3	30
10	Hormonal, Metabolic and Hemodynamic Adaptations to Glycosuria in Type 2 Diabetes Patients Treated with Sodium-Glucose Co-Transporter Inhibitors. <i>Current Diabetes Reviews</i> , 2019, 15, 314-327.	0.6	11
11	Impaired left ventricular diastolic function in T2<sc>DM</sc> patients is closely related to glycemic control. <i>Endocrinology, Diabetes and Metabolism</i> , 2018, 1, e00014.	1.0	6
12	Endogenous Glucose Production and Hormonal Changes in Response to Canagliflozin and Liraglutide Combination Therapy. <i>Diabetes</i> , 2018, 67, 1182-1189.	0.3	44
13	Initiating therapy in patients newly diagnosed with type 2 diabetes: Combination therapy vs a stepwise approach. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 497-507.	2.2	33
14	Glucose lowering and vascular protective effects of cycloset added to <sc>GLP</sc>â€1 receptor agonists in patients with type 2 diabetes. <i>Endocrinology, Diabetes and Metabolism</i> , 2018, 1, e00034.	1.0	9
15	Empagliflozin and Kinetics of Renal Glucose Transport in Healthy Individuals and Individuals With Type 2 Diabetes. <i>Diabetes</i> , 2017, 66, 1999-2006.	0.3	67
16	Effects of a metabolic syndrome selfâ€management programme for women with preâ€diabetes. Focus on Alternative and Complementary Therapies, 2015, 20, 74-80.	0.1	2
17	Assessment of Pancreatic &#946;-Cell Function: Review of Methods and Clinical Applications. <i>Current Diabetes Reviews</i> , 2014, 10, 2-42.	0.6	179
18	Acute insulin resistance stimulates and insulin sensitization attenuates vascular smooth muscle cell migration and proliferation. <i>Physiological Reports</i> , 2014, 2, e12123.	0.7	10

#	ARTICLE	IF	CITATIONS
19	Mechanisms of Glucose Lowering of Dipeptidyl Peptidase-4 Inhibitor Sitagliptin When Used Alone or With Metformin in Type 2 Diabetes. <i>Diabetes Care</i> , 2013, 36, 2756-2762.	4.3	52
20	Potential role of insulin signaling on vascular smooth muscle cell migration, proliferation, and inflammation pathways. <i>American Journal of Physiology - Cell Physiology</i> , 2012, 302, C652-C657.	2.1	22
21	Elevated Toll-Like Receptor 4 Expression and Signaling in Muscle From Insulin-Resistant Subjects. <i>Diabetes</i> , 2008, 57, 2595-2602.	0.3	319
22	Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2008, 294, E846-E852.	1.8	144
23	Relationship between Vascular Reactivity and Lipids in Mexican-Americans with Type 2 Diabetes Treated with Pioglitazone. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 1256-1262.	1.8	22
24	Relationship Between Hepatic/Visceral Fat and Hepatic Insulin Resistance in Nondiabetic and Type 2 Diabetic Subjects. <i>Gastroenterology</i> , 2007, 133, 496-506.	0.6	500
25	Comprehensive assessment of postischemic vascular reactivity in Hispanic children and adults with and without diabetes mellitus. <i>Pediatric Diabetes</i> , 2006, 7, 329-335.	1.2	13
26	Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases. <i>Diabetes/Metabolism Research and Reviews</i> , 2006, 22, 423-436.	1.7	373
27	Pioglitazone Reduces Hepatic Fat Content and Augments Splanchnic Glucose Uptake in Patients With Type 2 Diabetes. <i>Diabetes</i> , 2003, 52, 1364-1370.	0.3	265
28	Effects of $\beta_2$ -adrenergic blockade on hepatic and renal glucose production during hypoglycemia in conscious dogs. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 1998, 275, E792-E797.	1.8	5